Letter to the Editor

Page 6

Recently published articles about Letter to the Editor

JCP
Possible Suicidal Risk With Daridorexant
Letter to the Editor

December 7, 2022

Instructions for use of the new anti-insomnia medication daridorexant mention cautious use in patients with history of suicidal behavior. This letter explores the factors that underlie this recommendation for...
, ,
JCP
Pregnancy Outcomes After SGA Exposure: Extracting More From the Data
Letter to the Editor

November 30, 2022

Malathi Perugula, MD, and colleagues call attention to design aspects of a recent study on antipsychotic use in pregnancy.
, , , et al
JCP
Reply to Perugula et al: Toward Improving Reliability of Safety Information on Drug Exposure in Pregnancy
Letter to the Editor

November 30, 2022

Naho Yakuwa, BPharm, responds to Perugula and colleagues about a recent study on SGA use during early pregnancy.
JCP
Stigma Kills Psychiatric Patients and Is Now Killing Clinical Research Too
Letter to the Editor

November 28, 2022

Robert M. Post, MD, argues that NIMH should abandon the RDoC framework and restore funding for clinical research.
JCP
Valproate Prescribing in Individuals of Childbearing Age
Letter to the Editor

October 12, 2022

Camille Tastenhoye, MD, and colleagues share data from a tertiary care women’s hospital that highlight opportunities for improvement in valproate prescribing practices.
, , , et al
JCP
Addressing the Problem of Prescription of Valproate to Women of Childbearing Age: Reply to Tastenhoye et al
Letter to the Editor

October 12, 2022

Chittaranjan Andrade, MD, responds to a letter by Tastenhoye et al and comments on his recent study on valproate prescription in women.

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe